Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Minerva Surgical (UTRS) Competitors

Minerva Surgical logo
Compare

UTRS vs. TTOO, AFIB, MOTS, WOK, and DRTSW

Should you buy Minerva Surgical stock or one of its competitors? MarketBeat compares Minerva Surgical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Minerva Surgical include T2 Biosystems (TTOO), Acutus Medical (AFIB), Motus GI (MOTS), WORK Medical Technology Group (WOK), and Alpha Tau Medical (DRTSW). These companies are all part of the "medical equipment" industry.

How does Minerva Surgical compare to T2 Biosystems?

Minerva Surgical (NASDAQ:UTRS) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Minerva Surgical has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.21, indicating that its share price is 721% more volatile than the broader market.

In the previous week, T2 Biosystems had 2 more articles in the media than Minerva Surgical. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for Minerva Surgical. Minerva Surgical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
T2 Biosystems Neutral

23.2% of T2 Biosystems shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by insiders. Comparatively, 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Minerva Surgical has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

Summary

Minerva Surgical beats T2 Biosystems on 6 of the 10 factors compared between the two stocks.

How does Minerva Surgical compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
Minerva Surgical Neutral

Minerva Surgical has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. Minerva Surgical's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
Minerva Surgical N/A N/A N/A

Acutus Medical has a beta of 6.08, indicating that its share price is 508% more volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market.

Minerva Surgical has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A

56.9% of Acutus Medical shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Minerva Surgical beats Acutus Medical on 7 of the 10 factors compared between the two stocks.

How does Minerva Surgical compare to Motus GI?

Minerva Surgical (NASDAQ:UTRS) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
Motus GI N/A N/A N/A

Motus GI has lower revenue, but higher earnings than Minerva Surgical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A
Motus GI$319K0.00-$12.87M-$14.69N/A

20.1% of Motus GI shares are owned by institutional investors. 8.5% of Minerva Surgical shares are owned by company insiders. Comparatively, 0.3% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Minerva Surgical's average media sentiment score of 0.00 equaled Motus GI'saverage media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
Motus GI Neutral

Minerva Surgical has a beta of 2.92, suggesting that its share price is 192% more volatile than the broader market. Comparatively, Motus GI has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Summary

Minerva Surgical beats Motus GI on 4 of the 7 factors compared between the two stocks.

How does Minerva Surgical compare to WORK Medical Technology Group?

Minerva Surgical (NASDAQ:UTRS) and WORK Medical Technology Group (NASDAQ:WOK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, Minerva Surgical's average media sentiment score of 0.00 equaled WORK Medical Technology Group'saverage media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
WORK Medical Technology Group Neutral

Minerva Surgical has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market. Comparatively, WORK Medical Technology Group has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
WORK Medical Technology Group N/A N/A N/A

WORK Medical Technology Group has lower revenue, but higher earnings than Minerva Surgical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A
WORK Medical Technology Group$9.81M0.00-$1.07MN/AN/A

Given Minerva Surgical's higher possible upside, analysts clearly believe Minerva Surgical is more favorable than WORK Medical Technology Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Surgical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Minerva Surgical beats WORK Medical Technology Group on 3 of the 5 factors compared between the two stocks.

How does Minerva Surgical compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTSW) and Minerva Surgical (NASDAQ:UTRS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Alpha Tau Medical's average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
Alpha Tau Medical Neutral
Minerva Surgical Neutral

Alpha Tau Medical has higher earnings, but lower revenue than Minerva Surgical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Tau MedicalN/AN/AN/AN/AN/A
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A

Company Net Margins Return on Equity Return on Assets
Alpha Tau MedicalN/A N/A N/A
Minerva Surgical N/A N/A N/A

Summary

Minerva Surgical beats Alpha Tau Medical on 1 of the 1 factors compared between the two stocks.

Get Minerva Surgical News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTRS vs. The Competition

Export
MetricMinerva SurgicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$53.33M$6.45B$12.34B
Dividend YieldN/A1.08%2.76%5.28%
P/E Ratio0.0018.6821.2225.65
Price / SalesN/A37.51553.9286.28
Price / CashN/A18.8743.4956.67
Price / BookN/A16.1510.377.14
Net Income-$34.11M-$20.25M$3.57B$335.98M

Minerva Surgical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTRS
Minerva Surgical
N/AN/AN/AN/A$1K$51.69MN/A160
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-99.9%$4K$7.68MN/A180
AFIB
Acutus Medical
N/A$0.00
flat		N/A-99.0%$3K$7.16MN/A340
MOTS
Motus GI
N/AN/AN/AN/A$1K$319KN/A30
WOK
WORK Medical Technology Group
0.7864 of 5 stars		$0.11
flat		N/A-100.0%$1K$9.85MN/A226

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UTRS) was last updated on 5/25/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel